Showing 1741-1750 of 2839 results for "".
- Revision Skincare Unveils New "The Science Is Black and White" Brand Campaignhttps://modernaesthetics.com/news/revision-skincare-unveils-new-the-science-is-black-and-white-brand-campaign/2473507/Revision Skincare is rolling out its new brand campaign: "The Science Is Black and White." The campaign, which emphasizes that there are no gray areas when it comes to results, speaks to both consumers and skincare providers. Revision Skincare will be cel
- Hair Relaxers Linked to Uterine Cancer in Black Womenhttps://modernaesthetics.com/news/hair-relaxers-linked-to-uterine-cancer-in-black-women/2473506/Long-term use of chemical hair relaxers by postmenopausal Black women may increase risk of uterine cancer, according to a new study by researchers at Boston University’s Black Women’s Health Study (BWHS). These products contain potentially harmful ingredients, including chem
- Galderma Gives Back: New “Facing Breast Cancer Together" Campaign Supports the National Breast Cancer Foundationhttps://modernaesthetics.com/news/galderma-gives-back-new-facing-breast-cancer-together-campaign-supports-the-national-breast-cancer-foundation/2473503/Galderma is launching a new campaign to provide education and support for breast cancer awareness as part of its nine-year partnership with National Breast Cancer Foundation (NBCF), Inc. The survival rate of breast cancer patients has significantly increased due to early diagnosis
- Will Platysma Prominence Be the Next Nod for BOTOX Cosmetic?https://modernaesthetics.com/news/will-platysma-prominence-be-the-next-nod-for-botox-cosmetic/2473497/Allergan Aesthetics’ BOTOX Cosmetic met all primary and secondary endpoints for the treatment of moderate to severe platysma prominence associated with platysma muscle activity, according to topline results from the second of three Phase 3 studies. The multicenter, randomized
- FDA Grants 510(k) Clearance to Venus the Versa Pro Systemhttps://modernaesthetics.com/news/fda-grants-510k-clearance-to-venus-the-versa-pro-system/2473495/The U.S. Food and Drug Administration has granted marketing clearance to Venus Concept Inc.’s Venus Versa Pro System. Venus Versa is customizable and upgradable and supports 10 optional applicators which utilize Venus Concept’s (MP)2, IPL and NanoFractional RF tec
- BOTOX Cosmetic, IFundWomen Launch Crowdfunding Campaignshttps://modernaesthetics.com/news/botox-cosmetic-and-ifundwomen-launch-crowdfunding-campaigns/2473493/Allergan Aesthetics announced the next chapter of the BOTOX Cosmetic and IFundWomen grant program with the launch of crowdfunding campaigns for the women entrepreneurs. The brand
- Cutera Introduces Secret DUOhttps://modernaesthetics.com/news/cutera-introduces-secret-duo/2473490/Cutera, Inc. is launching Secret DUO, a skin resurfacing and revitalization platform that utilizes dual non-ablative fractional technologies. Each modality can be used individually or in combination to target a wide range of aesthetic indications. Secret DUO is equipped
- Cutera, Inc. Appoints Jeff Jones as Chief Operating Officerhttps://modernaesthetics.com/news/cutera-inc-appoints-jeff-jones-as-chief-operating-officer/2473482/Jeff Jones is Cutera, Inc.’s new Chief Operating Officer, effective August 28, 2023. Mr. Jones will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for end-to-end operations, including manufacturing, quality, supply chain, fi
- Delnova Demonstrates Proof of Concept for ReViVoxhttps://modernaesthetics.com/news/delnova-demonstrates-proof-of-concept-for-revivox/2473478/Delnova’s ReViVox showed reversal or muscle paralysis or weakness in a small cohort of healthy subjects. ReViVox is being developed to resolve side effects that may result from botulinum neurotoxin treatments. In the proof-of-concept study, volunteer subj
- 10xBio Completes Enrollment of Phase 2b Trial of Novel Drug for Submental Body Contouringhttps://modernaesthetics.com/news/10xbio-completes-enrollment-of-phase-2b-trial-of-novel-drug-for-submental-body-contouring/2473477/10xBio completed enrollment in a repeat treatment study of its novel injectable drug for submental body contouring. The drug, 10